DE69713336D1 - Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren - Google Patents
Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von TumorenInfo
- Publication number
- DE69713336D1 DE69713336D1 DE69713336T DE69713336T DE69713336D1 DE 69713336 D1 DE69713336 D1 DE 69713336D1 DE 69713336 T DE69713336 T DE 69713336T DE 69713336 T DE69713336 T DE 69713336T DE 69713336 D1 DE69713336 D1 DE 69713336D1
- Authority
- DE
- Germany
- Prior art keywords
- tumors
- cells
- treatment
- production
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96105157 | 1996-03-30 | ||
PCT/EP1997/001541 WO1997037004A1 (en) | 1996-03-30 | 1997-03-26 | Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69713336D1 true DE69713336D1 (de) | 2002-07-18 |
DE69713336T2 DE69713336T2 (de) | 2002-12-05 |
Family
ID=8222631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69713336T Expired - Fee Related DE69713336T2 (de) | 1996-03-30 | 1997-03-26 | Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren |
Country Status (8)
Country | Link |
---|---|
US (1) | US6399054B1 (de) |
EP (1) | EP0914416B1 (de) |
JP (1) | JP2000515364A (de) |
AU (1) | AU2160297A (de) |
CA (1) | CA2250394A1 (de) |
DE (1) | DE69713336T2 (de) |
ES (1) | ES2177964T3 (de) |
WO (1) | WO1997037004A1 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7541184B2 (en) * | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US20040175373A1 (en) * | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
ES2422193T3 (es) * | 2002-06-28 | 2013-09-09 | Life Technologies Corp | Métodos para restaurar el repertorio inmune en pacientes con defectos inmunológicos relacionados con la autoinmunidad y trasplante de órganos o de células madre hematopoyéticas |
US20050084967A1 (en) * | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
US7592143B2 (en) * | 2003-04-18 | 2009-09-22 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
EP1961065A4 (de) | 2005-10-31 | 2009-11-11 | Oncomed Pharm Inc | Zusammensetzungen und verfahren zur diagnostizierung und behandlung von krebs |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
EP2125887A4 (de) | 2007-01-24 | 2010-11-10 | Oncomed Pharm Inc | Zusammensetzungen und verfahren zur behandlung und diagnostizierung von krebs |
SG183742A1 (en) | 2007-05-21 | 2012-09-27 | Alderbio Holdings Llc | Antibodies to il-6 and use thereof |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
MX2009012493A (es) * | 2007-05-21 | 2010-01-20 | Alder Biopharmaceuticals Inc | Metodos de humanizacion de anticuerpo de conejo novedosos y anticuerpos de conejo humanizados. |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
SI2307051T1 (sl) | 2008-07-08 | 2015-04-30 | Oncomed Pharmaceuticals, Inc. | Notch-vezavna sredstva in antagonisti ter postopki njihove uporabe |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
NZ592338A (en) | 2008-09-26 | 2012-11-30 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US9452227B2 (en) * | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US8323649B2 (en) * | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
MX2012005927A (es) | 2009-11-24 | 2012-11-23 | Alder Biopharmaceuticals Inc | Anticuerpos para il-6 uso de los mismos. |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
EP2335721A1 (de) * | 2009-12-21 | 2011-06-22 | Institut Pasteur | Streptavidin und Biotin-enthaltendes Antigensversorgungssystem |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
CN102958534B (zh) | 2010-01-13 | 2014-11-05 | 昂考梅德药品有限公司 | Notch1结合剂及其使用方法 |
CA2794674A1 (en) | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
WO2012071561A2 (en) | 2010-11-23 | 2012-05-31 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of anemia |
WO2014066328A1 (en) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
CA2899353A1 (en) | 2013-02-04 | 2014-08-07 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
WO2023137471A1 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
WO2023137472A2 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
WO2024064642A2 (en) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for modulating t cell function |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987004628A1 (en) * | 1986-01-30 | 1987-08-13 | Fred Hutchinson Cancer Research Center | Immunoselection method |
IT1245748B (it) * | 1990-12-21 | 1994-10-14 | Mini Ricerca Scient Tecnolog | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego |
EP0711345A1 (de) * | 1993-07-26 | 1996-05-15 | Dana Farber Cancer Institute | B7-2: ctl a4/cd 28 "gegen rezepter" |
-
1997
- 1997-03-26 ES ES97914312T patent/ES2177964T3/es not_active Expired - Lifetime
- 1997-03-26 AU AU21602/97A patent/AU2160297A/en not_active Abandoned
- 1997-03-26 EP EP97914312A patent/EP0914416B1/de not_active Expired - Lifetime
- 1997-03-26 DE DE69713336T patent/DE69713336T2/de not_active Expired - Fee Related
- 1997-03-26 WO PCT/EP1997/001541 patent/WO1997037004A1/en active IP Right Grant
- 1997-03-26 CA CA002250394A patent/CA2250394A1/en not_active Abandoned
- 1997-03-26 JP JP09534912A patent/JP2000515364A/ja active Pending
-
1998
- 1998-09-29 US US09/161,998 patent/US6399054B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2000515364A (ja) | 2000-11-21 |
US6399054B1 (en) | 2002-06-04 |
CA2250394A1 (en) | 1997-10-09 |
AU2160297A (en) | 1997-10-22 |
EP0914416B1 (de) | 2002-06-12 |
EP0914416A1 (de) | 1999-05-12 |
WO1997037004A1 (en) | 1997-10-09 |
DE69713336T2 (de) | 2002-12-05 |
ES2177964T3 (es) | 2002-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69713336D1 (de) | Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren | |
DE60043035D1 (de) | Verfahren zur Herstellung von laminierten Ringen und Wärmebehandlungsvorrichtung zur Verwendung bei diesem Verfahren | |
ATE349428T1 (de) | Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen | |
DE59804783D1 (de) | Eisenoxidrotpigmente, Verfahren zur Herstellung von Eisenoxidrotpigmenten und deren Verwendung | |
DE59503593D1 (de) | Verfahren zur Herstellung von wasserverdünnbaren Urethanharzen und deren Verwendung | |
DE69816758D1 (de) | Synthetisches quarzglas zur verwendung in uv-strahlung und verfahren zu seiner herstellung | |
DE3887537D1 (de) | Verbandmaterial für wundbehandlung und teilchen zur verwendung in seiner herstellung. | |
DE69729284D1 (de) | Filmbildende zusammensetzungen von antihyperalgesischen opiaten und deren verwendung zur behandlung von hyperalgesie | |
DE69535674D1 (de) | Verfahren zur herstellung von l-valin und l-leucin | |
DE69821548D1 (de) | Vernetzte Polyaminsäure und deren Verfahren zur Herstellung | |
DE69512288D1 (de) | Verfahren zur Herstellung von Hexafluorpropan und Perfluorpropan | |
DE59508922D1 (de) | Verfahren zur Herstellung von Aminopropylalkoxysilanen in Gegenwart von geformten polymeren Rhodiumkomplex-Katalysatoren und deren Verwendung | |
DE69734296D1 (de) | Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b | |
DE59504187D1 (de) | Verfahren zur Herstellung von ultrareinem Bisphenol-A und dessen Verwendung | |
DE69810735D1 (de) | Zusammensetzung für die Behandlung von Wasser und deren Verfahren zur Herstellung | |
DE59610741D1 (de) | Verfahren zur Herstellung von Deckelmaterial sowie dessen Verwendung | |
DE59403959D1 (de) | Verfahren zur Herstellung von Diurethanen und ihrer Verwendung zur Herstellung von Diisocyanaten | |
DE59500700D1 (de) | Verfahren und Mittel zur Herstellung von purpurfarbenen Dekoren | |
DE60031100D1 (de) | Hapten modifizierte tumorzellen und verfahren zur herstellung und deren verwendung | |
DE69531132D1 (de) | Blattförmiger Sauerstoff-Absorber und Verfahren zur Herstellung | |
DE69711974D1 (de) | Verfahren zur Reinigung von 2,6-Dimethylnaphthol und dessen Verwendung bei der Herstellung von 2,6-Naphtholdicarbonsäure | |
DE60027429D1 (de) | Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien | |
DE59711559D1 (de) | Verfahren zur Herstellung von nicht-wässrigen Dispersionen und deren Verwendung | |
DE69714141D1 (de) | Verfahren zur Herstellung von normalen und überbasischen Phenolaten | |
ATA67490A (de) | Verfahren zur herstellung von kationischen lackbindemitteln und deren verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |